Assoc. Prof. Sophie Yacoub


Assoc. Prof. Sophie Yacoub, BM, MRCP, PhD, MSc, DTM&H


Dengue Research Group Head – Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

Honorary Consultant, Infectious Diseases and General Medicine- London North West Healthcare NHS Trust



Sophie is the head of the Dengue Research Group at the Oxford University Clinical Research Unit (OUCRU-Vietnam) and is a Wellcome Trust Clinical Career Development Fellow. She is a Physician in Infectious Diseases and General Medicine and holds an honorary consultant appointment at London North West University Healthcare NHS Trust in the UK. She has a PhD from Imperial College London and an MSc from the London School of Hygiene and Tropical Medicine. She is a member of the Royal College of Physicians in London. Her work has been supported by grants from the Wellcome Trust, NMRC Singapore, the WHO, British Heart Foundation and the Royal Society of Tropical Medicine.
Sophie is currently leading a large translational programme of dengue research, focusing on pathogenesis studies, precision medicine clinical trials and innovative technology centered on wearable devices, physiological monitoring and utilizing AI for medical imaging and clinical decision support systems. The group is also investigating the impact of climate change and global heating on dengue and other climate-sensitive diseases in Southeast Asia, through integration of novel digital technologies, remote patient monitors, mHealth initiatives and AI methodologies. The overall aim of the group is to improve dengue clinical outcomes in Viet Nam and globally.


Google scholar  

5 key recent research articles:


    1. 1. Pley C, Evans M, Lowe R, Montgomery H, Yacoub S. Digital and technological innovation in vector-borne disease surveillance to predict, detect, and control climate-driven outbreaks. Lancet Planet Health. 2021 Oct;5(10):e739-e745.
    1. 2. NL Vuong, PK Lam, DKY Ming, HT Le Duyen, NM Nguyen, DTH Tam, Chau NVV, Lum LC, Pleités E, Simmons CP, Rosenberger K, Jaenisch T, Bell D, Acestor N, Halleux C, Olliaro P, Wills B, Geskus R, Yacoub S. Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes. eLife 2021 Jun 22;10:e67460. 2021
    1. 3. McBride A, Mehta P, Rivino L, Ramanan AV, Yacoub S. Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought? The Lancet Microbe 2021 April 20
    1. 4. Nguyet MN, Chanh HQ, Tam HT, Vuong NL, Xuan Chau NT, Vinh Chau NV, Phong NT, Trieu HT, Hue TH, Rivino L, Gallagher P, Jones NK, Kestelyn E, Yacoub S. Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO) Wellcome Open Res. 2020 Jul 6;5:160.
    1. 5. Gan E, Duyen TL, Trieu H, Wills B, Seidah N, Ooi EE, Yacoub S. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J Clin Invest. 2020 Jul 9:137536.